Results 121 to 130 of about 15,200 (191)

Combined Anti-CD20/Anti-CD38 Therapy in Posttransplant Focal Segmental Glomerulosclerosis Recurrence: A Retrospective, International, Multicenter Study. [PDF]

Transplant Direct
Cravedi P, Maggiore U, Mortari G, Alberici F, La Manna G, Goes N, Bouvier N, Comai G, Mehr AP, Gentile M, Palmisano A, Gessaroli E, Barbuto S, Caridi G, Bigatti C, Magnasco A, Bossini N, Kajana X, Spennacchio A, Gallon L, Ghiggeri GM, Vincenti F, Hullekes FE, Mehta RV, Riella LV, Verrina EE, Angeletti A.   +26 more
europepmc   +1 more source

Efficacy and Safety of Daratumumab, Lenalidomide and Dexamethasone Therapy in the First Relapse of Multiple Myeloma Patients - Real World Data from Hungary. [PDF]

J Hematol
Lovas S, Obajed Al-Ali N, Farkas K, Pinczes LI, Varga G, Mikala G, Rajnics P, Kosztolanyi S, Plander M, Pettendi P, Varoczy L.   +10 more
europepmc   +1 more source

Ablation of CD38 in multiple myeloma cells leads to an aggressive phenotype in a mouse xenograft model. [PDF]

Blood Adv
Dyer MR, Zheleznyak A, Teubner EN, Prior JL, Manion B, Jing Z, Sharma AK, Du J, Tang R, Fiala MA, DiPersio JF, Veis D, O'Neal J, Berezin MY, Shokeen M.   +14 more
europepmc   +1 more source

Daratumumab inhibits acute myeloid leukemia metabolic capacity by blocking mitochondrial transfer from mesenchymal stromal cells [PDF]

, 2020
Bowles, Kristian M., Collins, Angela, Di Palma, Federica, Hellmich, Charlotte, Jibril, Aisha, Kumar, Prakritt, Marlein, Christopher R., Mistry, Jayna J., Moore, Jamie A., Pillinger, Genevra, Rushworth, Stuart A.   +10 more
core   +2 more sources

The addition of CD38 monoclonal antibody to triplet regimens improves survival in newly diagnosed multiple myeloma with high-risk cytogenetics: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Front Immunol
Hu B, Fang D, Jiang L, Li T, Chen K, Cao J, Wang J.   +6 more
europepmc   +1 more source

Ixazomib-Lenalidomide-Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: A Hungarian Real-World Analysis. [PDF]

J Clin Med
Sánta H, Regáli L, Váróczy L, Szita V, Wiedemann Á, Varju L, Rejtő L, Bartha NS, Máté D, Masszi A, Plander M, Kosztolányi S, Hussain A, Pettendi P, Istenes I, Szomor Á, Reményi P, Masszi T, Varga G, Mikala G.   +19 more
europepmc   +1 more source

Addition of daratumumab to standard triplet regimens achieved better survival in newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Front Oncol
Hu B, Wang J, Fang D, Jiang L, Li T, Cao J.   +5 more
europepmc   +1 more source

Daratumumab in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials. [PDF]

Cancers (Basel)
Wang C, Xu Z, Jiang M, Chen Y, Lan Y.
europepmc   +1 more source

First Report of Daratumumab Therapy in Refractory THSD7A-Positive Membranous Nephropathy. [PDF]

Kidney Int Rep
Ribes D, Faguer S.
europepmc   +1 more source

Targeting Wnt/β-catenin signaling enhances the efficacy of anti-CD38 immunotherapy in multiple myeloma. [PDF]

Neoplasia
Li H, Chen Y, Gregorova M, Yang T, Zhang X, Yu X, Wang Z, Hua H, Ye L, Qi X, Spaargaren M, Pals ST, Ren Z.   +12 more
europepmc   +1 more source